Abstract Number: 1976 • 2014 ACR/ARHP Annual Meeting
Elevation and Functional Activity of Interferon Omega in Human Systemic Lupus Erythematosus
Background/Purpose IFNα is emerging as a clinically validated target in SLE yet it is currently unclear if other type I IFNs are contributing to the…Abstract Number: 1624 • 2014 ACR/ARHP Annual Meeting
The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE
Background/Purpose Monocytes are increasingly recognised to play a key role in the pathogenesis of SLE. Different subpopulations of monocytes contribute to the disease through dysregulated pro…Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…Abstract Number: 2551 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
Background/Purpose: Atacicept is a fusion protein that inhibits B cell stimulating factors BLyS and APRIL. We examined the pharmacodynamic (PD) effects of atacicept in patients…Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…